



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/19, 31/195, 31/38, 9/08		A1	(11) International Publication Number: WO 97/24114 (43) International Publication Date: 10 July 1997 (10.07.97)
(21) International Application Number: PCT/IB96/01461		(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 23 December 1996 (23.12.96)			
(30) Priority Data: MI95A002777 28 Aug 97/20 wos, 28 December 1995 (28.12.95) IT			
(71) Applicant (<i>for all designated States except US</i>): DOMPE' S.P.A. [IT/IT]; Via Campo di Pite, I-67100 L'Aquila (IT).		Published <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): GENTILE, Marco [PT/IT]; Via del/Torciuro, 27, I-67100 L'Aquila (IT); BOLTRI, Luigi [IT/IT]; Via Matteo da Leonessa, 7, I-67100 L'Aquila (IT); CLAVENNA, Gaetano [IT/IT]; Corso Magenta, 5, I-20100 Milan (IT).			
(74) Agent: BENEDUCE, Gianna; Via Poggibonsi, 7, I-20146 Milan (IT).			
(54) Title: PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING AMMONIUMALKYL SALTS OF 2-ARYLPROPIONIC ACIDS			
(57) Abstract			
A pharmaceutical composition for parenteral administration having anti-inflammatory and analgesic properties which contain, as active principle, alkylammonium salts of 2-arylpropionic acids.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Description

Parenteral pharmaceutical compositions containing ammoniumalkyl salts of 2-arylpropionic acids.

The object of the present invention consists of 5 pharmaceutical compositions suitable for parenteral administration which contain alkylammonium salts of 2-arylpropionic acids.

In particular, although the parenteral pharmaceutical compositions of the invention are suitable to be 10 obtained with any 2-arylpropionic acid having antiinflammatory activity, they preferably contain, as 2-arylpropionic acid, ketoprofen or 3-benzoyl- α -methylbenzeneacetic acid, ibuprofen or 2-(4-isobutylphenyl)propionic acid, naproxen or (S)-6-15 methoxy- α -methyl-naphthaleneacetic acid and tiaprofenic acid or 5-benzoyl- α -methyl-2-thiopheneacetic acid, the ketoprofen being the 2-arylpropionic acid particularly preferred.

One of the advantages represented by the 20 pharmaceutical compositions of the invention is that it allows for the administration of the non-steroid antiinflammatory substance by a route of administration, the parenteral one, which does not show side effects as shown by the pharmaceutical forms 25 administered by topical route such as, for example, creams, lotions, gels or ointments which, because of their easy methods of application, are widely used. It is in fact known from literature on the subject that topical administration of non-steroid anti-30 inflammatory drugs can, in a more or less serious manner, provoke damage to the patient's skin due to

the fotolability of the drug which, in the presence of light, undergoes a degradation process, the products of which interfere negatively on the cellular membrane by the formation of free radicals.

- 5 The pharmaceutical compositions of the invention represent, moreover, a notable improvement as far as stability and convenience of use and safety are concerned with respect to the compositions already on the market containing the same anti-inflammatory
10 drugs.

A decisively more advantageous aspect of said pharmaceutical compositions is that their administration causes uneasiness but tolerable, with respect to the pain, sometimes intense, caused by the
15 compositions for parenteral use on the market containing the same anti-inflammatory drugs.

In particular, as far as ketoprofen is concerned, the relative smallness of the side effects and the recognised effectiveness in the symptomatic treatment
20 of rheumatoid arthritis, in osteoarthritis, in ankylosing spondylitis, of acute painful articular and periarticular symptoms of the musculoskeletal system, in gout and in dysmenorrhea, in the treatment of pain and inflammation which accompanies or follows
25 orthopaedic operations, have made of such a drug one of the active principles of largest use in oral administration among anti-inflammatory non-steroid drugs of current therapeutical use.

The analgesic and anti-inflammatory effect of
30 ketoprofen has been, in large measure, correlated to its capacity, or more specifically, to the capacity of

its S-enantiomer, of inhibiting the prostaglandin synthesis. More recently, it has been recognised that the R-enantiomer, which in human beings does not undergo an appreciable metabolic conversion in the S-5 antipode, has its own analgesic property, mediated by mechanism of action which, even though not fully clarified, seem to be completely independent from the prostaglandin synthesis block.

Pharmaceutical formulations for parenteral use 10 containing as active principle ketoprofen and/or its enantiomers are thought to be particularly useful in the treatment of acute exacerbations of painful manifestations and as adjuvant in the symptomatic therapy of pain in persons suffering from terminal 15 cancer, in individual therapeutic treatment as in association with muscle relaxants, pain-killers and central analgesics.

The 2-arylpropionic acids with anti-inflammatory activity of the present invention are made up of 20 highly lipophilic carboxylic acids and as such are scarcely soluble in water. Nonetheless it is possible to prepare solutions of said acids, after salification in aqueous vehicles containing a surplus of a hydrate, of a bicarbonate and/or of an alkaline carbonate or an 25 earth alkaline carbonate such as, for example, sodium hydroxide, sodium bicarbonate, of a preferably basic

α -aminoacid or of a hydroxyalkylamine, eventually in the presence of preservatives and excipients and/or 30 dispersing agents.

Said solutions of the 2-arylpropionic acids present a

gradual instability easily evidenced from a progressive yellowing, sometimes followed by turbidity and by separation of floccules, phenomena which become more noticeable with the temperature's increase and 5 after the solution's prolonged exposure to the light. To overcome said difficulty recourse was made to lyophilized pharmaceutical formulations from which the injectable solution is reconstituted just at the moment of use by means of solubilization in the proper 10 solvent. These solutions contain, furthermore, variable quantities of preserving substances among which are mainly used the p-hydroxybenzoate of methyl and propyl, and supporting materials in excess such as, for example, glycine, to ensure the volume and 15 compactness of the lyophilized substance itself. The use, together with the active principles, of a ponderal excess of supporting materials imply that the constituted solutions present pH values which vary from 6.5 to 7.3 and definitely result hypertonic. In 20 fact, osmolarity values are measured covering an interval from 650 to 1150 mOsm/kg, which are not very compatible with the isotonicity of biological fluids which present values comprised between 275 and 295 mOsm/kg. As a result, the administration of such 25 solutions causes pain to the patient and moreover superficial liquid effusions can come about. The presence of remarkable quantities of excipients and of the preserving agents in the solution can moreover be the cause of risks deriving from the patient's 30 individual susceptibility to said substances.

It is known that, on the English market, formulations

have long been introduced for the extemporary use consisting of a ketoprofen solution in a mainly aqueous medium containing an excess of l-arginine, benzylic alcohol and citric acid; said solutions, 5 which present a global pH of about 6.7 are supplied in dark glass containers for a better control of their stability.

The pharmaceutical compositions suitable for parenteral use object of the present invention, are 10 made up of aqueous solutions of alkylammonium salt of 2-arylpropionic acids chosen from the group consisting of ketoprofen, ibuprofen, naproxen and tiaprofenic acid in racemic or in enantiomeric form, which present osmolarity values comprised in the range 270-310 15 mOsm/kg and pH values comprised in the range 7.0-7.5.

As alkylammonium bases are utilised bases which include alkyl radicals eventually substituted with hydroxy radicals: in the case that the alkylammonium base exists in a racemic or enantiomeric form, the 20 salts can comprise either one or the other of said forms. Bases particularly preferred are α -aminoacids such as lysine and particularly preferred is the salt formed with the forms of said aminoacid having the natural configuration. Another preferred base is the 25 dropropazine or 3-(4-phenyl-1-piperazinyl)-1,2-propanediols. The salifying acid is preferably employed in its racemic form even though salts formed from its separate enantiomers are comprised within the scope of the invention.

30 The particularly preferred salts are those of (R,S)-ketoprofen with d,l-lysine and with l-lysine

respectively described in US 4,279,926 (21.07.81) and BE 882.889 (14.05.80). Other salts, as for example the R- or S-ketoprofen salts with the separated stereoisomers of lysine and dropropizine, are also 5 known and have been described in WO 94/20449 (15.09.94).

According to the process of the invention, the pharmaceutical compositions suitable for parenteral use containing salts of a 2-arylpropionic acid 10 selected from the group consisting of ketoprofen, ibuprofen, naproxen and tiaprofenic acid with alkylammonium bases are prepared by solubilizing in an inert-gas atmosphere and away from light, in an aqueous solution, at a pH ranging from 7.0 and 7.5, 15 the alkylammonium salt of the chosen 2-arylpropionic acid.

The use of an inert gas during the preparation of the solutions and their subsequent conservation allows the reaching of such a degree of stability so as to avoid 20 a recourse to the use of preservatives and co-solvents such as, for example, alcohols or glycols for preventing the progressive yellowing of the solutions. Inert gases particularly preferred are those which are chemically inert with solvents and solutes and are 25 compatible with the foreseen pharmaceutical use: these are, as example, nitrogen and the rare gases helium and argon and their mixtures.

Besides to grant the composition of the invention a good tolerability, the lack of benzyl alcohol or other 30 solvent, except water for injectable preparations, also gives the consumer a precise information about

the quality of the composition itself. In fact, should the pharmaceutical composition undergo alterations due to an incorrect storage, the appearing of a characteristic whitish opalescence indicates these 5 alterations immediately and therefore the pharmaceutical composition will not be administered. The appearance of said opalescence representing a very sensitive index of the pharmaceutical quality of the active principle contained in the composition of the 10 invention, is a guarantee of the quality of the composition and furthermore it represents a noticeable improvement in respect to those compositions which contain co-solvent agents, such as in particular benzyl alcohol, and consequently do not make evident 15 the possible presence of alterations which would cause the pharmaceutical quality of the composition not anymore acceptable.

The packaging, in suitable containers of dark glass optionally disposed in a box wherein each container is 20 separately packaged, as well as the other characteristic of the composition of the invention assures a full stability to the product as demonstrated by the tests carried out.

Moreover it has been observed that the pH 25 adjustment of the injectable solution between 7.0 and 7.5, allows for the bringing about of, not only a useful increment of osmolarity towards that degree of hyperosmosis which better than

a slight hypo-osmosis adapts itself to a good tolerability of the injectable solution, but also an ulterior increment in the stability of the darkening solution and to the turbidity whether in tests of
5 thermic accelerated stability or in exposure to light. For the adjustment of the pH and consequently of the osmolarity of the 2-arylpropionic acid salts, mixtures have been used of C₃-C₅ hydroxy di- and tri-carboxylic acids and the alkaline and alkaline earth salts
10 thereof chosen in the group consisting of the tartronic, malic, tartaric and citric acids. Particularly preferred is the use of citric acid combined with the sodium hydroxy and/or sodium citrate.

15 The dark glass containers are preferably borosilicate phials rendered opaque to light radiations having 290 to 450 nm wave lengths.

Hereunder are given some non-limitative examples of some embodiments of the invention.

20 Example 1

Working sheltered from light, in an atmosphere and under bubbling nitrogen, 37.5 g (c.a.0.195M) of citric acid and 22.5 g (0.5625M) of sodium hydroxide are dissolved in 12 l of sterile water for injectable
25 preparations, previously de-aerated. To the solution so obtained is added under stirring 1.2 kg (3M) of (R,S)-ketoprofen salt of d,l-lysine controlling the pH of the solution and eventually adjusting it to values varying from 7.0 to 7.5 with additions of sodium
30 hydroxide.

After complete dissolution of the salt, the volume of

the solution is brought to 15 l with sterile water for injectable preparations, previously de-aerated, and stirring is continued for another 15 minutes to ensure the total homogeneity of the solution. Nitrogen is
5 left to bubble on the solution for 15 minutes. Working is kept under pressure and in a nitrogen atmosphere, the solution is filtered through 0.22 micron cartridges, and collected in suitable shielded containers appropriately protected from exposure to
10 the UV light radiations and then run into the machine for filling phials for distribution in 2 ml glass ampoules, which are sealed in a nitrogen atmosphere.
After sterilisation, the single phials are placed in containers which are made to hold one or more phials.
15 If desired, the single phial holders can be protected individually by films which make them opaque to the transmission of light.

Example 2

In a similar manner, as described in the preceding
20 Example, working is carried out by substituting the d,l-lysine salt of (R,S)-ketoprofen with the d,l-lysine salt of (R,S)-naproxen which is prepared from 0.2M of d,l-lysine dissolved in 700 ml of water to which is added, heating to the boiling point
25 temperature, 0.202M of finely sub-divided (R,S)-naproxen. From the reaction mixture the salt separates by removing the water for distillation.

Claims

1. A pharmaceutical composition suitable for parenteral administration having anti-inflammatory and analgesic property, characterized by the fact that it contains an alkylammonium salt of a 2-arylpropionic acid selected from the group consisting of ketoprofen, ibuprofen, naproxen, tiaprofenic acid, in racemic as well as in enantiomeric form, in an aqueous solution having an osmolarity between 270 and 310 mOsm/kg and at a pH in the range between 7.0 and 7.5, said solution being free of preservatives and of supporting substances and being prepared and kept in a gas-inert atmosphere.
2. A pharmaceutical composition according to claim 1, characterized by the fact that the inert gas is nitrogen.
3. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the d,l-lysine salt of (R,S)-ketoprofen and the inert gas is nitrogen.
4. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the l-lysine salt of (R,S)-ketoprofen.
5. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the l-lysine salt of R-ketoprofen.
6. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the l-dropropizine salt

- of R-ketoprofen.
7. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the tromethamine salt of S-ketoprofen.
8. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the tromethamine salt of R-ketoprofen.
- 10 9. A pharmaceutical composition according to claim 1, characterized by the fact that the alkylammonium salt of the 2-arylpropionic acid is the 1-lysine salt of S-ketoprofen.
10. Process for the preparation of the pharmaceutical composition according to claim 1, characterized by that an alkylammonium salt of a 2-arylpropionic acid selected from the group consisting of ketoprofen, ibuprofen, naproxen and tiaprofenic acid is suitably dissolved in water for injectable preparation at a pH between 7.0 and 7.5 in an atmosphere of an inert gas and away from light.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 96/01461

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 31/19, A 61 K 31/195, A 61 K 31/38, A 61 K 9/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	EP, A, 0 070 714 (THE UPJOHN COMPANY) 26 January 1983 (26.01.83), claim 4; abstract; page 1, lines 26-27; page 8, lines 15-18 in connection with examples 5,10. --	1-10
X, Y	US, A, 5 206 262 (DONATI E. et al.) 27 April 1993 (27.04.93), abstract; claim 8; column 1, lines 36-49; column 2, line 44 - column 3, line 17. --	1-10
X, Y	GB, A, 2 059 768 (KAHAN I.) 29 April 1981 (29.04.81), abstract; claims 1,7,10,11,	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search
20 February 1997

Date of mailing of the international search report

26.03.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

MAZZUCCO e.h.

INTERNATIONAL SEARCH REPORT

-2-

International Application No.
PCT/IB 96/01461

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	14.21; page 1, lines 111-118; examples 9,13; page 2, lines 70-80. -- US, A, 4 877 620 (LOEW D. et al.) 31 October 1989 (31.10.89), claims 1.6; column 3, lines 41-43; examples 4,5. --	1-10
X, Y	DE, A, 2 508 895 (SPA SOCIETA PRODOTTI ANTI- BIOTICI S.P.A.) 18 September 1975 (18.09.75), claims 1-3,5,6; page 4, paragraphs 1,3; page 8, paragraph 3. --	1-10
X, Y	EP, A, 0 136 470 (MERCKLE GMBH) 10 April 1985 (10.04.85), claims 1.7; page 2, line 7 - page 4, line 14; page 5, lines 7-25. --	1-10
X, Y	CHEMICAL ABSTRACTS, vol. 94, no. 20, issued 1981, May 18, (Columbus, Ohio, USA), DOMPE FARMACEUTICI S.P.A. "Lysine m-benzoylhydratropate and pharmaceutical compo- sitions containing it", page 386, columns 1-2, no. 162 745q; & BE 882 889. --	1-10
X, Y	WO, A, 94/20 449 (DOMPE FARMACEUTICI S.P.A.) 15 September 1994 (15.09.94), abstract; claims 1-11,16-19; page 2, lines 4-9; page 3, line 27 - page 4, line 11; page 5, lines 10-27; page 9, line 28 - page 10, line 1 (cited in the application). --	1-10
X, Y	WO, A, 89/04 658 (SUNSHINE A.) 01 June 1989 (01.06.89), claim 37; page 9, lines 13-17; page 20, line 29 - page 21, line 11. --	1-10

INTERNATIONAL SEARCH REPORT

International Application No.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

PCT/IB 96/01461

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	<p>WO, A, 93/17 677 (SEPRACOR, INC.) 16 September 1993 (16.09.93), claims 1,7-9,12,16,25,27,30, 31; page 6, lines 12-26; page 12, lines 12-26. --</p>	1-10
X, Y	<p>WO, A, 93/16 689 (RHONE-POULENC RORER S.A.) 02 September 1993 (02.09.93), claims 1,5,6; page 3, lines 20-25; page 4, lines 9-20,27-31. -----</p>	1-10

ANHANG

zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

ANNEX

to the International Search Report to the International Patent Application No.

ANNEXE

au rapport de recherche international relatif à la demande de brevet international n°

PCT/IB 96/01461 SAE 148377

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Orientierung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The Office is in no way liable for these particulars which are given merely for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document du brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1 70714	26-01-83	BE A1 893878 DE CO 3270988 ES B1 70714 IT A0 8222266 IT A 1165359 JP A2 58024517 US A 4447451	19-01-83 12-04-83 07-08-83 06-07-83 28-01-87 14-02-83 08-05-84
US A 5206262	27-04-93	EP A2 9001544 EP A3 9001544 IT A0 91001804 IT A 1255007	07-01-93 07-04-93 01-07-91 11-10-91
GB A1 2059768		HU BE 183156 AT 8629 AU A1 59455780 AU B2 538893 CA A1 1148159 CY A 15597 DE C 1511594 DE CO 30686920 DK A 2640780 DK B 160762 DK D 52078 EP A1 52078 EP B1 801964 FI A 68827 FI B 68827 FI C 68827 GR A 492782 HK A 49982 IE B 49982 IL A0 60557 IL A1 60557 JP A2 56018980 JP B4 3009114 KR B1 8400421 MY A2 556187 NO A 801866 NO B 193430 NO C 193430 NO D 71102 PT A 143187 SG A 143187 ZA A 8003714 US A 4312870	28-04-84 15-08-84 08-01-81 30-08-84 14-06-83 04-11-81 20-08-84 16-04-90 28-09-91 07-01-81 25-07-84 22-12-80 31-11-87 13-05-87 25-06-87 30-06-86 16-05-80 11-05-84 23-02-81 07-02-91 02-04-84 31-11-87 22-11-80 09-11-85 12-07-86 01-06-90 10-07-87 24-06-81 26-01-82
US A 4877620	31-10-89	DE A1 3639038 DE C2 3639038 IL A0 84478 IL A1 6316616 US A2 6316616 US A 6511939 US A 8941939 US A 89708400 EP A1 2673221 AT E1 5074631 DE CO 3669103 EP B1 2673221 GR T3 3000292	28-07-88 06-02-97 29-04-88 08-07-97 16-07-88 01-08-88 01-07-94 29-06-88 18-05-88 15-05-90 05-04-90 28-02-90 15-03-91
DE A1 2508895	18-09-75	AU A1 78803775 AU A2 89264246 CA A1 2508895 DE B1 4732416 DE S1 2265378 FR A1 2265378 FR B1 1497044 GB A 50126818 JP A2 50126818 JP B4 59012680	09-09-74 30-04-80 32-01-80 07-04-88 01-12-76 03-10-75 04-08-78 05-01-78 06-10-75 24-03-84

			NL A	7502644	09-09-75
			US A	4279926	21-07-81
EP A2	136470	10-04-85	AT E	39323	15-01-89
			CA A1	1234050	15-03-89
			DE A2	1234051	21-01-89
			DE A3	1234470	08-01-89
			EP A3	1234470	08-01-89
			JP A2	60064910	14-04-89
			US A	4593044	04-06-89
			US B1	4593044	21-06-89
WO A1	9420449	15-09-94	AU A1	62905/94	26-09-94
			EP A1	703893	03-04-94
			IT A1	94500348	25-02-94
			IT A0	93500447	09-03-94
WO A1	8904658	01-06-89	AT E	138568	15-06-94
			AU A1	29014/89	14-06-94
			AU B2	610978	30-05-94
			CA A1	12344640	07-03-94
			DE C0	12055320	04-07-94
			DE T2	12055320	24-10-94
			EP A1	1246431	20-12-89
			JP B2	28068280	18-09-89
			US A	4062124	18-09-89
			US B2	4062124	09-10-94
WO A1	9317677	16-09-93	AU A1	37989/93	05-10-94
			AU B2	673998	05-12-94
			AU A1	70334/93	19-12-94
			EP A1	6302339	28-12-94
			EP A4	6302532	18-01-95
			HU A0	9448820	28-07-94
			JP T2	75097057	01-08-94
			US A	53231000	19-07-94
			CA AA	2094683	23-10-94
WO A1	9316689	02-09-93	EP A1	627916	14-12-94
			FR A1	2687916	03-09-94
			FR B1	2687916	05-05-94
			JP T2	7504410	18-05-94

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 96/01461

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 31/19, A 61 K 31/195, A 61 K 31/38, A 61 K 9/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	EP, A, 0 070 714 (THE UPJOHN COMPANY) 26 January 1983 (26.01.83), claim 4; abstract; page 1, lines 26-27; page 8, lines 15-18 in connection with examples 5,10. --	1-10
X, Y	US, A, 5 206 262 (DONATTI E. et al.) 27 April 1993 (27.04.93), abstract; claim 8; column 1, lines 36-49; column 2, line 44 - column 3, line 17. --	1-10
X, Y	GB, A, 2 059 768 (KAHAN I.) 29 April 1981 (29.04.81), abstract; claims 1,7,10,11, --	1-10

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A" document defining the general state of the art which is not considered to be of particular relevance
- *'E" earlier document published on or after the international filing date
- *'L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O" document referring to an oral disclosure, use, exhibition or other means
- *'P" document published prior to the international filing date but later than the priority date claimed

'T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'Z" document member of the same patent family

Date of the actual completion of the international search
20 February 1997Date of mailing of the international search report
26.03.97

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

MAZZUCCO e.h.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 96/01461

-2-

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	14.21; page 1, lines 111-118; examples 9,13; page 2, lines 70-80. --	
X,Y	US, A, 4 877 620 (LOEW D. et al.) 31 October 1989 (31.10.89), claims 1,6; column 3, lines 41-43; examples 4,5. --	1-10
X,Y	DE, A, 2 508 895 (SPA SOCIETA PRODOTTI ANTI- BIOTICI S.P.A.) 18 September 1975 (18.09.75), claims 1-3,5,6; page 4, paragraphs 1,3; page 8, paragraph 3. --	1-10
X,Y	EP, A, 0 136 470 (MERCKLE GMBH) 10 April 1985 (10.04.85), claims 1,7; page 2, line 7 - page 4, line 14; page 5. lines 7-25. --	1-10
X,Y	CHEMICAL ABSTRACTS, vol. 94, no. 20, issued 1981, May 18, (Columbus, Ohio, USA), DOMPE FARMACEUTICI S.P.A. "Lysine m-benzoylhydratropate and pharmaceutical compo- sitions containing it", page 386, columns 1-2, no. 162 745q; & BE 882 889. --	1-10
X,Y	WO, A, 94/20 449 (DOMPE FARMACEUTICI S.P.A.) 15 September 1994 (15.09.94). abstract; claims 1-11,16-19; page 2, lines 4-9; page 3, line 27 - page 4, line 11; page 5, lines 10-27; page 9, line 28 - page 10, line 1 (cited in the application). --	1-10
X,Y	WO, A, 89/04 658 (SUNSHINE A.) 01 June 1989 (01.06.89). claim 37; page 9, lines 13-17; page 20, line 29 - page 21, line 11.	1-10

INTERNATIONAL SEARCH REPORT

International Application No.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/IR 96/01461
Category *	Description of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO, A, 93/17 677 (SEPRACOR, INC.) 16 September 1993 (16.09.93), claims 1,7-9,12,16,25,27,30, 31; page 6, lines 12-26; page 12, lines 12-26. -- 	1-10
X,Y	WO, A, 93/16 689 (RHONE-POULENC RORER S.A.) 02 September 1993 (02.09.93), claims 1,5,6; page 3, lines 20-25; page 4, lines 9-20,27-31. ---- 	1-10

			NL A 7502644	09-09-75
			US A 4279726	21-07-81
EP A2	136470	10-04-85	AT E 357223	15-01-82
			CA A1 12482050	15-01-88
			DE A1 12482401	25-02-85
			DE A1 12482491	25-01-85
			EP A1 12482470	08-06-85
			EP B1 12482470	21-12-88
			JP A2 60064918	13-04-85
			US A 45930444	03-05-85
			US B1 45930444	21-06-85
WD A1	9420449	15-09-94	AU A1 62905794	26-09-94
			EE A1 702893	03-04-94
			IT A0 94500348	25-02-94
			IT A0 93500447	09-03-94
WD A1	8904658	01-06-89	AT E 1205688	15-06-86
			AU A1 2901299	14-06-89
			AU B2 610598	30-05-91
			DE A1 12056448	07-03-95
			DE C0 12056520	04-07-96
			DE T2 12056520	24-10-96
			EP A1 12446431	20-12-89
			EP B1 12446431	20-07-89
			JP A2 25028888	18-09-89
			US A 48686124	09-10-90
WD A1	9317677	16-09-93	AU A1 37989794	05-10-93
			AU B2 673998	05-12-96
			AU A1 70334796	19-12-96
			EP A1 63023396	28-12-94
			EP A4 63023396	01-01-95
			HU A0 94082682	15-08-95
			HU A0 688262	15-07-95
			JP A2 7507057	03-08-95
			US A 25031000	19-07-94
			CA AA 2094683	23-10-94
WD A1	9316689	02-09-93	EP A1 62027918	14-12-94
			EP A1 25027774	06-06-96
			EP T2 7504410	06-05-96